C. Gouttefangeas

发表

Thinking outside the gate: single-cell assessments in multiple dimensions.

N. Aghaeepour, R. Scheuermann, P. Qiu, 2015, Immunity.

Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future

M. Welters, Cliburn Chan, C. Ottensmeier, 2020, Cancer Immunology.

Identification of tumor‐associated MHC class I ligands by a novel T cell‐independent approach

Cécile Gouttefangeas, H. Rammensee, S. Stevanović, 2000, European journal of immunology.

Modeling flow cytometry data for cancer vaccine immune monitoring

Cliburn Chan, Jacob Frelinger, Cécile Gouttefangeas, 2010, Cancer Immunology, Immunotherapy.

Single-Domain Antibodies for Targeting, Detection, and In Vivo Imaging of Human CD4+ Cells

M. Schaller, B. Pichler, U. Rothbauer, 2021, Frontiers in Immunology.

Lipofection with Synthetic mRNA as a Simple Method for T-Cell Immunomonitoring

T. Kündig, E. Guenova, S. Pascolo, 2021, Viruses.

Harmonization of Immune Biomarker Assays for Clinical Studies

Sylvia Janetzki, Cedrik M Britten, Marij J P Welters, 2011, Science Translational Medicine.

Generation of TCR-engineered reference cell samples to control T-cell assay performance.

S. H. van der Burg, C. Gouttefangeas, Nicole Bidmon, 2020, Methods in enzymology.

Automated Analysis of Flow Cytometry Data to Reduce Inter-Lab Variation in the Detection of Major Histocompatibility Complex Multimer-Binding T Cells

Alexandra J. Lee, Jonathan A. Rebhahn, R. Scheuermann, 2017, Front. Immunol..

Cryopreservation of MHC Multimers: Recommendations for Quality Assurance in Detection of Antigen Specific T Cells

S. H. van der Burg, S. Hadrup, C. Britten, 2014, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy

S. Stevanović, A. Stenzl, J. Bedke, 2013, World Journal of Urology.

Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols

S. H. van der Burg, M. Welters, B. Renard, 2012, Cancer Immunology, Immunotherapy.

Towards patient‐specific tumor antigen selection for vaccination

H. Rammensee, T. Weinschenk, C. Gouttefangeas, 2002, Immunological reviews.

Investigation of the antioxidant capacity of caramels: Combination of laboratory assays and C. elegans model

M. Prost, C. Gouttefangeas, F. Tessier, 2021 .

Universitet Gs-coupled receptor signaling and sleep regulate integrin activation of human antigen-specific T cells

J. Born, H. Rammensee, S. Soekadar, 2019 .

Gαs-coupled receptor signaling and sleep regulate integrin activation of human antigen-specific T cells

J. Born, H. Rammensee, S. Soekadar, 2019, The Journal of experimental medicine.

Soluble heat shock protein 70 members in patients undergoing allogeneic hematopoietic cell transplantation.

H. Rammensee, L. Kanz, W. Bethge, 2016, Transplant immunology.

Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation

H. Rammensee, P. Pereira, A. Boss, 2011, Cell Stress and Chaperones.

A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer

H. Rammensee, S. Stevanović, P. Pereira, 2019, Front. Immunol..

Analysis of tumor antigen‐specific T cells and antibodies in cancer patients treated with radiofrequency ablation

H. Rammensee, S. Stevanović, P. Pereira, 2011, International journal of cancer.

Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes

K. Grønbæk, A. Stenzl, J. Hennenlotter, 2013, Oncoimmunology.

Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study

S. H. van der Burg, M. Welters, V. Bronte, 2016, Cancer Immunology, Immunotherapy.

Human platelets express heat shock protein receptors and regulate dendritic cell maturation.

H. Rammensee, H. Schild, P. Schwarzmaier, 2002, Blood.

The Tübingen approach: identification, selection and validation of tumor-associated HLA peptides for cancer therapy

H. Rammensee, S. Stevanović, O. Schoor, 2004, Cancer Cell International.

Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an HLA-A2-restricted epitope derived from indoleamine 2,3 dioxygenase

I. Svane, R. Andersen, P. Straten, 2013, Journal of Immunotherapy for Cancer.

Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase

I. Svane, R. Andersen, P. thor Straten, 2013, Clinical Cancer Research.

Designing a therapeutic SARS-CoV-2 T-cell-inducing vaccine for high-risk patient groups

H. Rammensee, S. Stevanović, G. Tabatabai, 2020 .

Integrin Activation Enables Sensitive Detection of Functional CD4+ and CD8+ T Cells: Application to Characterize SARS-CoV-2 Immunity

J. Born, H. Rammensee, S. Stevanović, 2021, Frontiers in Immunology.

Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8+ T cells with detection by ELISPOT and HLA-multimer staining

S. H. van der Burg, M. Welters, P. Romero, 2014, Cancer Immunology, Immunotherapy.

Functional T lymphocytes infiltrate implanted polyvinyl alcohol foams during surgical wound closure therapy

J. Müller, P. Ruck, C. Gouttefangeas, 2001, Clinical and experimental immunology.

Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry

S. H. van der Burg, M. Welters, A. Scheffold, 2015, Cancer Immunology, Immunotherapy.

A Simple and Rapid Method for Quality Control of Major Histocompatibility Complex–Peptide Monomers by Flow Cytometry

H. Rammensee, S. Pascolo, C. Gouttefangeas, 2017, Frontiers in Immunology.

Thrombocyte HLA molecules retain nonrenewable endogenous peptides of megakaryocyte lineage and do not stimulate direct allocytotoxicity in vitro.

H. Rammensee, S. Stevanović, C. Gouttefangeas, 2000, Blood.

T-cell immune monitoring assays to guide the development of new cancer vaccines

M. Welters, M. Kalos, C. Ottensmeier, 2011 .

Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial

H. Rammensee, K. Brasso, M. Røder, 2020, Journal for ImmunoTherapy of Cancer.

Characterisation of the volatile fraction of aromatic caramel using heart-cutting multidimensional gas chromatography.

C. Dacremont, A. Prot, E. Guichard, 2015, Food chemistry.

AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial

H. Kalbacher, S. Perez, C. Baxevanis, 2013, Cancer Immunology, Immunotherapy.

CD8+ T-cell response against MUC1-derived peptides in gastrointestinal cancer survivors

H. Rammensee, S. Stevanović, T. Weinschenk, 2005, Cancer Immunology, Immunotherapy.

Erratum to “Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient”

H. Rammensee, S. Stevanović, O. Kohlbacher, 2016, Journal of hepatology.

Study of the CD3-associated T-cell receptors reveals further differences between T-cell acute lymphoblastic lymphoma and leukemia.

L. Boumsell, C. Gouttefangeas, A. Bensussan, 1990, Blood.

Utilization of two different T cell receptors by T cell acute lymphoblastic lymphoma and leukemia.

L. Boumsell, C. Gouttefangeas, A. Bensussan, 1990, Nouvelle revue francaise d'hematologie.

Gs-coupled receptor signaling and sleep regulate integrin activation of human antigen-specific T cells

S. Soekadar, T. Lange, C. Gouttefangeas, 2019 .

Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2

Ihor O. Arkhypov, J. Utikal, P. Altevogt, 2022, Frontiers in Immunology.

The CD39 molecule defines distinct cytotoxic subsets within alloactivated human CD8‐positive cells

L. Boumsell, C. Gouttefangeas, A. Bensussan, 1992, European journal of immunology.

A vaccine in renal cell carcinoma: are we nearing reality?

A. Stenzl, J. Bedke, C. Gouttefangeas, 2012, Expert review of anticancer therapy.

Chitin oligomers directly promote lymphoid innate and adaptive immune cell activation

A. Weber, C. Gouttefangeas, K. Fuchs, 2022, bioRxiv.

The fungal ligand chitin directly binds TLR2 and triggers inflammation dependent on oligomer size

B. Maček, C. D. Dela Cruz, T. Roger, 2018, EMBO reports.

Defining the critical hurdles in cancer immunotherapy

Zhigang Tian, Sylvia Janetzki, Cedrik M Britten, 2011, Journal of Translational Medicine.

Characterization of Odor-Active Compounds in Aromatic Caramel by GC-Olfactometry and GC-Mass Spectrometry

C. Dacremont, E. Guichard, C. Gouttefangeas, 2014 .

CAF-immune cell crosstalk and its impact in immunotherapy

Anna Schöllhorn, C. Gouttefangeas, Ana Maia, 2022, Seminars in Immunopathology.

T cell assays and MIATA: the essential minimum for maximum impact.

M Roederer, S Janetzki, G Pawelec, 2012, Immunity.

Simultaneous Identification of Functional Antigen-Specific CD8+ and CD4+ Cells after In Vitro Expansion Using Elongated Peptides

C. Gouttefangeas, Jennifer R Richardson, E. Rusch, 2022, Cells.

Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performance.

Cedrik M Britten, Marij J P Welters, Ugur Sahin, 2018, Journal of immunological methods.

CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy

Anna Schöllhorn, C. Gouttefangeas, Jennifer R Richardson, 2021, Cancers.

Actively personalized vaccination trial for newly diagnosed glioblastoma

J. Castle, H. Rammensee, S. Stevanović, 2018, Nature.

PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma

H. Rammensee, T. Zichner, A. Stenzl, 2019, Cancer Immunology Research.

Personalized cancer vaccines: adjuvants are important, too

H. Rammensee, C. Gouttefangeas, 2018, Cancer Immunology, Immunotherapy.

Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas.

Hans-Georg Rammensee, Cécile Gouttefangeas, Arnulf Stenzl, 2009, Cancer research.

Immunotherapy of renal cell carcinoma

H. Rammensee, S. Stevanović, A. Stenzl, 2006, Cancer Immunology, Immunotherapy.

Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient

Oliver Kohlbacher, Sven Nahnsen, Mathias Walzer, 2016, Journal of hepatology.

Integrated functional genomics approach for the design of patient-individual antitumor vaccines.

Hans-Georg Rammensee, Cécile Gouttefangeas, Steffen Walter, 2002, Cancer research.

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

H. Rammensee, S. Stevanović, O. Kohlbacher, 2020, Nature immunology.

Impact of curative radiotherapy on the immune status of patients with localized prostate cancer

H. Rammensee, D. Zips, F. Eckert, 2018, Oncoimmunology.

This information is current as Cell Assays Their Use To Control the Performance of T Generation of TCR-Engineered T Cells and

U. Şahin, S. Kreiter, P. Simon, 2015 .

Patient-individual Antitumor Vaccines Integrated Functional Genomics Approach for the Design of Updated

H. Rammensee, S. Stevanović, M. Schirle, 2002 .

Cytomegalovirus Infection

C. Franceschi, G. Pawelec, S. Koch, 2007, Annals of the New York Academy of Sciences.

International conference: progress in vaccination against cancer-2006 (PIVAC 6), Granada, Spain

G. Pawelec, F. Garrido, N. Aptsiauri, 2007, Cancer Immunology, Immunotherapy.

The fungal ligand chitin directly binds and signals inflammation dependent on oligomer size and TLR2

B. Maček, C. D. Dela Cruz, Nadine A Schilling, 2018, bioRxiv.

Cathepsin W expressed exclusively in CD8+ T cells and NK cells, is secreted during target cell killing but is not essential for cytotoxicity in human CTLs.

Eva Tolosa, Cécile Gouttefangeas, E. Weber, 2009, Experimental hematology.

Radiotherapy planning parameters correlate with changes in the peripheral immune status of patients undergoing curative radiotherapy for localized prostate cancer

H. Rammensee, D. Zips, F. Paulsen, 2021, Cancer Immunology, Immunotherapy.

Optimization in Detection of Antigen‐Specific T Cells Through Differentially Labeled MHC Multimers

M. Welters, S. Hadrup, C. Gouttefangeas, 2019, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Profiling of primary peripheral blood- and monocyte-derived dendritic cells using monoclonal antibodies from the HLDA10 Workshop in Wollongong, Australia

Cécile Gouttefangeas, C. Gouttefangeas, H. Bühring, 2015, Clinical & translational immunology.

A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

H. Rammensee, S. Stevanović, B. Pichler, 2019, Journal of Immunotherapy for Cancer.

Adhering to adhesion: assessing integrin conformation to monitor T cells

Stoyan Dimitrov, Cécile Gouttefangeas, Juliane Schuhmacher, 2019, Cancer Immunology, Immunotherapy.

Promiscuous survivin peptide induces robust CD4+ T‐cell responses in the majority of vaccinated cancer patients

H. Rammensee, S. Stevanović, A. Stenzl, 2012, International journal of cancer.

Activated integrins identify functional antigen-specific CD8+ T cells within minutes after antigen stimulation

J. Born, H. Rammensee, M. Schindler, 2018, Proceedings of the National Academy of Sciences.

The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays

A. Mackensen, C. Gouttefangeas, A. Mander, 2007, Cancer Immunology, Immunotherapy.

Novel multi‐peptide vaccination in Hla‐A2+ hormone sensitive patients with biochemical relapse of prostate cancer

Cécile Gouttefangeas, Klaus Dietz, Arnulf Stenzl, 2009, The Prostate.

Toward the harmonization of immune monitoring in clinical trials: Quo vadis?

C. Gouttefangeas, S. Janetzki, S. H. van der Burg, 2007, Cancer Immunology, Immunotherapy.

More Than Just Tumor Destruction: Immunomodulation by Thermal Ablation of Cancer

H. Rammensee, P. Pereira, H. Salih, 2011, Clinical & developmental immunology.

Response definition criteria for ELISPOT assays revisited

Cedrik M. Britten, Z. Moodie, L. Price, 2010, Cancer Immunology, Immunotherapy.

A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit

H. Kalbacher, S. Perez, M. Papamichail, 2015, Cancer Immunology, Immunotherapy.

[Prostate carcinoma: vaccination as a new option for treatment].

A. Stenzl, J. Bedke, C. Gouttefangeas, 2012, Der Urologe. Ausg. A.

Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas

H. Rammensee, S. Stevanović, O. Schoor, 2006, Clinical Cancer Research.

Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells

S. H. van der Burg, G. Ferrari, E. Kaempgen, 2009, Cancer Immunology, Immunotherapy.

High frequencies of functionally impaired cytokeratin 18‐specific CD8+ T cells in healthy HLA‐A2+ donors

H. Rammensee, S. Stevanović, G. Pawelec, 2005, European journal of immunology.

Immune Signatures and Survival of Patients With Metastatic Melanoma, Renal Cancer, and Breast Cancer

G. Pawelec, B. Weide, K. Wistuba-Hamprecht, 2020, Frontiers in Immunology.

Generation of TCR-Engineered T Cells and Their Use To Control the Performance of T Cell Assays

S. H. van der Burg, U. Şahin, S. Kreiter, 2015, The Journal of Immunology.

A framework for T cell assays

S. H. van der Burg, C. Britten, C. Gouttefangeas, 2015, Oncotarget.

Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program

C. Gouttefangeas, A. Mander, M. J. P. Welters, 2010, Cancer Immunology, Immunotherapy.

High frequency of human cytomegalovirus (HCMV)-specific CD8+-T cells detected in a healthy CMV-seropositive donor

H. Rammensee, S. Stevanović, C. Gouttefangeas, 2002, Cellular and Molecular Life Sciences CMLS.

Immunorejuvenation in the elderly.

G. Pawelec, S. Koch, C. Gouttefangeas, 2006, Rejuvenation research.

Immunoguiding, the Final Frontier in the Immunotherapy of Cancer

M. Welters, J. Galon, C. Britten, 2014 .

The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study

Cedrik M. Britten, Cécile Gouttefangeas, Marij J. P. Welters, 2012, Cancer Immunology, Immunotherapy.

Harmonization of the intracellular cytokine staining assay

Cedrik M. Britten, Cécile Gouttefangeas, Marij J. P. Welters, 2012, Cancer Immunology, Immunotherapy.

Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters

Cliburn Chan, Hans-Georg Rammensee, Cedrik M. Britten, 2015, Cancer Immunology, Immunotherapy.

Validation of Immunomonitoring Methods for Application in Clinical Studies: The HLA‐Peptide Multimer Staining Assay

H. Rammensee, C. Ottensmeier, C. Gouttefangeas, 2018, Cytometry. Part B, Clinical cytometry.

Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases.

H. Rammensee, S. Stevanović, A. Stenzl, 2017, European urology focus.

Supplementary Issue: Array Platform Modeling and Analysis (b) Managing Multi-center Flow Cytometry Data for Immune Monitoring

Cliburn Chan, Jennifer Enzor, Janet Staats, 2022 .

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

S. Stevanović, O. Kohlbacher, J. Karbach, 2020, Nature Immunology.

Abstract B124: Personalized peptide vaccination based on patient-individual tumor-specific variants induces T-cell responses in pediatric patients

H. Rammensee, S. Stevanović, O. Kohlbacher, 2019, Novel Vaccine Platforms and Combinations.

GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma.

H. Rammensee, S. Stevanović, W. Wick, 2018 .

Problem solving for tumor immunotherapy

H. Rammensee, C. Gouttefangeas, 2000, Nature Biotechnology.

Radiofrequency ablation: the percutaneous approach.

P. Pereira, C. Claussen, A. Boss, 2006, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Single-domain antibodies for targeting, detection and in vivo imaging of human CD4+ cells

M. Schaller, B. Pichler, U. Rothbauer, 2021, bioRxiv.

Integrin activation enables simultaneous and sensitive detection of functional virus-specific CD4+ and CD8+ T cells

J. Born, H. Rammensee, S. Stevanović, 2020 .

Hierarchical Modeling for Rare Event Detection and Cell Subset Alignment across Flow Cytometry Samples

Cliburn Chan, Jacob Frelinger, Mike West, 2013, PLoS Comput. Biol..

Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups

H. Rammensee, G. Tabatabai, M. Reth, 2021, Vaccines.

Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity

H. Rammensee, S. Stevanović, S. Nedospasov, 2013, Cancer Immunology Research.

Staining of activated ß2-integrins in combination with CD137 and CD154 for sensitive identification of functional antigen-specific CD4+ and CD8+ T cells

Anna Schöllhorn, C. Gouttefangeas, S. Dimitrov, 2023, Frontiers in Immunology.

Integrin activation enables rapid detection of functional Vδ1+ and Vδ2+ γδ T cells

G. Pawelec, K. Wistuba-Hamprecht, Anna Schöllhorn, 2022, European journal of immunology.

1st EMBL/DFG Women in Science Network Conference Heidelberg 2016

R. Stripecke, I. Förster, C. Gouttefangeas, 2016, European journal of immunology.

T-cell dysregulation caused by chronic antigenic stress: the role of CMV in immunosenescence?

G. Pawelec, C. Gouttefangeas, 2006, Aging clinical and experimental research.

HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients.

H. Rammensee, M. Loeffler, E. Simeone, 2018 .

Phase I/II multicenter trial of a novel therapeutic cancer vaccine, HepaVac-101, for hepatocellular carcinoma.

F. Izzo, P. Ascierto, L. Buonaguro, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

The good and the bad of T cell cross-reactivity: challenges and opportunities for novel therapeutics in autoimmunity and cancer

C. Gouttefangeas, R. Klein, A. Maia, 2023, Frontiers in Immunology.

Abstract 2396: IMA950: A novel multi-peptide cancer vaccine for treatment of glioblastoma

H. Rammensee, S. Stevanović, O. Schoor, 2010 .

Differential proliferative responses in subsets of human CD28+ cells delineated by BB27 mAb.

E. Meffre, L. Boumsell, C. Gouttefangeas, 1994, International Immunology.

Immunosenescence, suppression and tumour progression

G. Pawelec, S. Koch, C. Gouttefangeas, 2006, Cancer Immunology, Immunotherapy.

76 Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal cell carcinoma

H. Rammensee, S. Stevanović, A. Stenzl, 2012 .

EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma: ROSALIE study.

J. Fagerberg, P. Wen, A. Idbaih, 2022, Journal of Clinical Oncology.

Two birds with one stone: human SIRPα nanobodies for functional modulation and in vivo imaging of myeloid cells

A. Rezza, B. Pichler, U. Rothbauer, 2023, bioRxiv.

SARS-CoV-2 T-cell epitopes define heterologous and COVID-19-induced T-cell recognition

H. Rammensee, S. Stevanović, O. Kohlbacher, 2020 .

Identification of tumor‐associated MHC class I ligands by a novel T cell‐independent approach

H. Rammensee, S. Stevanović, M. Schirle, 2000, European journal of immunology.

In vitro differentiation from a pluripotent human CD4+CD8+ thymic cloned cell into four phenotypically distinct subsets.

L. Boumsell, C. Gouttefangeas, A. Bensussan, 1990, Journal of immunology.